Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase II Clinical Study of CAR-T-19 Injection in the Treatment of CD19-positive Relapsed/refractory B-cell Acute Lymphoblastic Leukemia(B-ALL) Under 25 Years of Age (inclusive)

NCT06179524 is registered in ClinicalTrials.gov with Beijing Yongtai Ruike Biotechnology Company Ltd as lead sponsor.

NCT NCT06179524
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06179524 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase II Clinical Study of CAR-T-19 Injection in the Treatment of CD19-positive Relapsed/refractory B-cell Acute Lymphoblastic Leukemia(B-ALL) Under 25 Years of Age (inclusive)
Lead sponsor
Beijing Yongtai Ruike Biotechnology Company Ltd
Phase
Phase 2
Overall status
Recruiting
Start date
January 3, 2024
Completion date
April 30, 2027
Enrollment
100 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

refractory b-cell acute lymphoblastic leukemia, relapsed b-cell acute lymphoblastic leukemia